chartexchange

Why Biohaven Catapulted 25% — And Why It Might Not Be Done Sprinting

Investor's Business Daily | Oct 22, 2026 9:24 AM EDT

Biohaven stock catapulted Thursday after the FDA said it would review the company's embattled drug, troriluzole.
The post Why Biohaven Catapulted 25% — And Why It Might Not Be Done Sprinting appeared first on Investor's Business Daily .

Read original article